Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T19:49:43.160Z.
Calculation as of: 2026-10-06T19:49:43.160Z.
Quote observation: 2026-10-06T19:45:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e8daa83f2db5fafa0746e2d75675d68491b64c400a2027f88c30977eae97731f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$348.81M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$354.03M
EBITDA Yield
N/A
TTM Avg
3.28%
3Y Avg
4.15%
5Y Avg
7.65%
Market Cap
$354.03M
EBITDA Yield
15.44%
TTM Avg
14.45%
3Y Avg
13.54%
5Y Avg
12.09%
Market Cap
$359.07M
EBITDA Yield
N/A
TTM Avg
3.23%
3Y Avg
3.23%
5Y Avg
3.23%
Market Cap
$359.83M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | $346.88M | N/A | N/A | N/A | N/A |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $348.81M | N/A | N/A | N/A | N/A |
| Relmada Therapeutics, Inc. (RLMD)vs › | $344.82M | N/A | N/A | N/A | N/A |
| Embecta Corp. (EMBC)vs › | $350.03M | 18.64% | 21.70% | 14.93% | 15.13% |
| Ocugen, Inc. (OCGN)vs › | $353.49M | N/A | N/A | N/A | N/A |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $354.03M | N/A | 3.28% | 4.15% | 7.65% |
| Viemed Healthcare, Inc. (VMD)vs › | $354.03M | 15.44% | 14.45% | 13.54% | 12.09% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.07M | N/A | 3.23% | 3.23% | 3.23% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $359.83M | N/A | N/A | N/A | N/A |
| Opus Genetics, Inc. (IRD)vs › | $361.26M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
